Patients from 22+ countriesPlan your visit →
lutetium-therapy
Second Opinions · 27 Aug 2026

Borderline PSMA-PET: Are You Eligible for Lu-177?

If your PSMA-PET scan came back 'borderline', your eligibility for lutetium Lu-177 vipivotide tetraxetan may not be a simple yes or no. This article explains what borderline positivity means, the criteria specialist teams actually use, and why a second expert read of your scan may change the answer.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 27 Aug 2026
Borderline PSMA-PET: Are You Eligible for Lu-177?

This article covers PSMA-targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). If your PSMA-PET scan shows 'borderline', 'equivocal', or 'low uptake', and your care team says you may not qualify for lutetium Lu-177 vipivotide tetraxetan (brand name: Pluvicto), this article explains what that means and what to ask next.

Quick answer: 'Borderline PSMA-PET positive' means your scan shows some PSMA protein on prostate cancer cells, but at roughly the same level or below normal liver tissue - the threshold used in the VISION trial to define eligibility. A borderline result doesn't automatically disqualify you. Your care team needs to know whether you have any PSMA-negative lesions, which tracer was used, and whether an experienced theranostics team has reviewed your entire scan.

What a PSMA-PET scan actually measures

PSMA stands for prostate-specific membrane antigen. It is a protein found on the surface of most prostate cancer cells. A PSMA-PET scan uses a small radioactive tracer that binds to this protein. Where PSMA is present, the scan lights up. Where it is absent or very low, the scan stays dark or dim.

The brightness of that signal we call uptake. It shows how much PSMA your cancer cells make. This matters because lutetium Lu-177 vipivotide tetraxetan works by attaching to that same PSMA protein and delivering targeted radiation to cancer cells. If PSMA levels are very low across all lesions, the treatment has fewer targets to reach.

For more information on how to read your imaging report, our guide on what your PSMA-PET results mean for Lu-177 eligibility covers the key terms in plain language.

The liver uptake standard: where the eligibility line sits

The most widely cited eligibility threshold comes from the VISION trial - the large international study that led to FDA approval of Pluvicto in March 2022 for adults with PSMA-positive mCRPC who had already received at least one androgen receptor pathway inhibitor and taxane-based chemotherapy.

The trial used a straightforward visual rule: at least one metastatic lesion had to show tracer uptake clearly greater than normal liver tissue. The liver is used as the reference because healthy liver tissue has a predictable level of PSMA uptake. Lesions clearly brighter than the liver are PSMA-positive. Lesions at roughly the same level, or below it, are not.

When your care team says a result is borderline, they usually mean one of these situations:

  • One or more lesions show uptake roughly equal to - but not clearly above - the liver.
  • Some lesions are clearly PSMA-positive, but others are not.
  • The pattern of uptake is mixed or uneven from site to site.

None of these situations automatically disqualifies you. But each requires careful, expert evaluation before deciding on treatment.

Does borderline uptake predict a poor response?

A study evaluating PSMA uptake thresholds before radioligand therapy, published on PubMed Central, found that some lesions with baseline uptake below the liver threshold still showed treatment response, while others progressed. The liver uptake threshold had limited ability to predict which individual lesions would later fail. Some lesions just below the threshold still respond to treatment.

That said, patients with predominantly low or borderline uptake tend to show lower overall response rates than patients with clearly positive, high-uptake disease. No definitive cutoff exists below which treatment always fails - which is why borderline cases need individual specialist assessment.

The Society of Nuclear Medicine and Molecular Imaging Appropriate Use Criteria for PSMA-617 recommend the VISION threshold - at least one lesion with uptake greater than liver - as the reference standard for patient selection, because those criteria were associated with overall survival benefit in the largest randomised trial.

The exclusion rule that often gets missed

Borderline results are only part of the eligibility picture. The VISION trial also excluded patients whose cancer had PSMA-negative dominant disease. Patients were excluded if one or more lesions above certain size thresholds showed uptake at the level of normal liver or below it. Those thresholds were:

  • A lymph node with a short-axis diameter of at least 2.5 cm.
  • A bone metastasis with a soft-tissue component of at least 1 cm in short-axis diameter.
  • A solid-organ metastasis of at least 1 cm in short-axis diameter.

If you have large, visible lesions that do not light up on PSMA-PET, this exclusion may matter more than whether your positive lesions are bright enough. Large PSMA-negative lesions suggest part of your cancer no longer makes PSMA - a pattern researchers call PSMA heterogeneity.

If your imaging shows 'mixed' or 'heterogeneous' disease, our article on what happens when PSMA imaging is negative in mCRPC explains what that means for eligibility and what options may remain.

Why the choice of tracer matters

Not all PSMA-PET tracers behave the same way. The VISION trial used Ga-68 PSMA-11 (gallium-68 gozetotide). Piflufolastat F-18 is also accepted for treatment selection in many countries. A third option - a SPECT scan using 99mTc-MIP-1404 - is available in some settings but produces different liver uptake values from PET-based tracers.

A peer-reviewed comparison published on PubMed Central found that eligibility rates for Lu-177 PSMA therapy differed depending on which tracer was used. The 99mTc-MIP-1404 SPECT tracer showed higher liver activity and lower lesion-to-liver ratios compared to Ga-68 PSMA-11 PET, meaning some patients who appeared borderline or ineligible with one tracer met the criteria with the other.

If your borderline result came from a SPECT scan rather than a PET scan, or from a tracer other than Ga-68 PSMA-11 or piflufolastat F-18, a second evaluation using a standard PET tracer may give a different answer. This is a practical reason to seek specialist review when a result falls near the threshold.

Reader variability and why a specialist review matters

Even with the same scan, different nuclear medicine specialists may read borderline results differently. A substudy of the VISION trial published in the Journal of Nuclear Medicine and available on PubMed Central assessed how consistently trained readers agreed when evaluating PSMA-PET scans for Lu-177 eligibility. Agreement was strong for clearly positive or clearly negative cases. For borderline or equivocal lesions, variation between readers was greater.

This reflects the complexity of real-world imaging, where contrast between a lesion and normal liver can be subtle. A borderline result read by a general radiologist may differ from one read by a specialist team that evaluates PSMA scans for treatment selection regularly, applying standard criteria specific to theranostics eligibility.

Our article on getting a second opinion on Lu-177 PSMA eligibility explains what documents to bring and how a specialist expert review typically works.

Other eligibility requirements beyond the scan

Your PSMA-PET result is one part of a broader eligibility picture. The FDA-approved indication for lutetium Lu-177 vipivotide tetraxetan requires that you have previously received at least one androgen receptor pathway inhibitor - such as enzalutamide or abiraterone - and at least one taxane-based chemotherapy regimen. Beyond these formal criteria, your care team will also consider kidney function, bone marrow reserve, and overall physical condition. These factors determine whether your team can safely give you therapy, regardless of scan positivity.

What to do if your result is borderline

Here are practical steps if your PSMA-PET report uses language like 'borderline', 'low uptake', 'equivocal', or 'heterogeneous disease':

  1. Get the full written report. Ask for the imaging report in writing. It should state which tracer was used, how lesion uptake compared to liver, and whether any PSMA-negative lesions were identified with their sizes recorded.
  2. Ask specifically about PSMA-negative lesions. Find out which lesions are PSMA-negative and whether they meet the VISION trial size thresholds.
  3. Ask about FDG-PET. If your team hasn't done this, discuss whether a dual-tracer scan would give you useful information before you decide.
  4. Seek a specialist second opinion. A nuclear medicine specialist with theranostics experience may interpret a borderline scan differently from a general radiologist, especially with standard eligibility criteria.
  5. Ask about clinical trials. Some trials and expanded access programmes use different eligibility windows. Your case might qualify under a different protocol even if it falls outside the VISION criteria.

If you are considering an expert imaging review before committing to a plan, you can request a second opinion through Art of Healing Cancer on whether Lu-177 is right for you - and what alternatives exist if not. The team reviews PSMA-PET scans alongside your full treatment history, rather than treating the scan as a standalone decision.

If Lu-177 PSMA therapy is not confirmed: what comes next

A borderline scan that ultimately falls short of eligibility criteria is hard to receive. But you still have options. A specialist theranostics team will typically discuss alternatives at the same consultation. These may include systemic therapies that don't require PSMA expression, clinical trials testing new approaches for mCRPC, or a plan to re-image later - since PSMA expression can change over time as disease evolves or treatment changes.

A definitive specialist assessment does more than confirm or rule out one treatment. It gives you a clear picture of where your cancer stands today, so your next step is based on complete information.

When to talk to your doctor

Speak with your oncologist or a nuclear medicine specialist if your PSMA-PET report uses terms like 'low uptake', 'borderline', 'equivocal', 'heterogeneous disease', or 'mixed positivity'. Ask which tracer was used, whether any lesions are PSMA-negative, how large they are, and whether a second read by a theranostics specialist would help. If your doctor said you're not a candidate for Lu-177 PSMA therapy, ask for the specific reason in writing so you can bring it to any second opinion.

You can also send your PSMA-PET scan for an eligibility review via the Lutetium Therapy contact form. If Lu-177 PSMA therapy isn't recommended as suitable, the review will also address what alternative approaches may be appropriate for your situation.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

What does 'borderline PSMA-PET positive' mean?

A borderline result means your scan shows some PSMA tracer uptake on prostate cancer lesions, but the signal is close to - rather than clearly above - the level of uptake in normal liver tissue. This liver-versus-lesion comparison is the main threshold from the VISION trial used to define who qualifies for lutetium Lu-177 vipivotide tetraxetan. A borderline result does not automatically disqualify you, but it requires specialist review to determine whether treatment is appropriate for your specific case.

Can I still receive Lu-177 PSMA therapy if my scan is borderline?

It depends on the full picture. If at least one lesion is clearly above the liver uptake threshold and no large PSMA-negative lesions are present, you may still meet eligibility criteria. Borderline results become more complicated when all lesions are at or below liver level, or when significant PSMA-negative disease is also present. A second opinion from a nuclear medicine specialist with theranostics experience is the most reliable way to get a clear answer.

What are PSMA-negative lesions and why do they affect eligibility?

PSMA-negative lesions are metastatic sites where cancer cells show low or absent PSMA expression on the scan. They do not light up the way PSMA-positive lesions do. The VISION trial excluded patients who had PSMA-negative lesions above certain size thresholds - lymph nodes 2.5 cm or larger in short-axis diameter, or solid-organ metastases 1 cm or larger - because these sites suggest the cancer has changed in ways that cannot be effectively targeted by PSMA-directed radiation.

Does the type of PSMA tracer used affect whether I qualify?

Yes. Different tracers produce different liver uptake values, which changes the lesion-to-liver ratio that determines eligibility. The VISION trial used Ga-68 PSMA-11. Piflufolastat F-18 is also accepted for treatment selection. A SPECT scan using 99mTc-MIP-1404 tends to show higher liver activity, which can make some borderline patients appear ineligible when they might qualify on a standard Ga-68 PET scan. If your scan used a different tracer, a review or repeat with an accepted PET tracer may change the result.

Why might two specialists read my borderline PSMA-PET scan differently?

Interpreting borderline PSMA-PET findings requires judgement, particularly when lesion uptake is close to liver level. A VISION trial substudy found strong agreement between trained readers on clearly positive or clearly negative cases, but greater variation on borderline findings. A second read from a specialist with specific theranostics and eligibility-review experience can sometimes produce a more favourable interpretation.

What happens if I do not qualify for Lu-177 PSMA therapy?

A specialist team will discuss alternative options at the same consultation. These may include systemic therapies that do not depend on PSMA expression, clinical trials evaluating other approaches for mCRPC, or a plan to re-image in the future since PSMA expression can change over time. A borderline eligibility result is a reason to seek a thorough evaluation from an experienced team - not a reason to stop exploring what may still be available.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

Borderline PSMA-PET: Lu-177 Eligibility Explained | lutetium-therapy